Can we use sputum to identify progression to RA in at-risk individuals? Sputum anti-CCP-IgA anti-CCP-IgG & RF-IgM positivity = 4-fold increase risk of classified RA in IgG CCP+ at-risk individuals. Sens 67% Spe 80% https://t.co/o6PCvxgYGM Abs #0533 #ACR22 #ACRBest @Rheumnow https://t.co/CxDjanjBKT

• Sputum RA-Associated Autoantibodies Independently Associate with Future Develop…

@erasmusmcintl @RheumNow Data here from @earlyarthritis (CATCH Canada cohort), similar results. It's not just pain differences - but that's real too. It's lots of things, but whatever the case we ignore sex and gender's impact in RA at our peril. ABST0532 #ACR22 @Janetbirdope @TheLancetRheum @RheumNow https://t.co/27uQmNAlPF

Emerging and exciting treatments in RA: #ACR22 preview https://t.co/5JtblF9MxE https://t.co/oYSiLguLkJ

• https://bit.ly/3hCseTa

Are DNA methylation marks the new seronegative RA biomarkers? Riskedal et al. propose a new model based on whole-blood DNAm profiles Sens 90%, Spe 88%, Accuracy 89% for classification of RA Accuracy RA Sero+ 100%, RA Sero- 75% https://t.co/3occAQPZ1u Abs#0531 #ACR22 @Rheumnow https://t.co/QXhMxyWC8g

• Development and Performance of a Diagnostic Precision Biomarker for Seronegativ…

18mo data of ARIAA study (6mo ABA in pre-RA): 12mo after discontinuation Progression to RA ABA 35% vs PBO 57% p=0.008 Improvement in synovitis, osteitis & tenosynovitis ABA 57% vs. 29% PBO Enough to move into clinical application? https://t.co/2CDN9M31mB Abs#0530 #ACR22 @Rheumnow https://t.co/R54AokGSiK

• Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Mo…

Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA and AS patients. Factors associated with MACE/VTE: age>65, HTN, DM, smoking, history CV event/VTE Abs#0510 @RheumNow #ACR22 https://t.co/AjtJF0p3QK

England et al. Influence of FVC on choice of b/tsDMARD in RA-ILD. FVC predicts hospitalisation and mortality. However, it did not appear to influence choice of b/tsDMARD. Overall 67% of RA-ILD patients initiated TNFi, weird! @rheumnow #ACR22 Abstr#245 https://t.co/swuNHv96WD https://t.co/vy5FUPnNjo

• Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcom…

Difficult to treat #rheumatoidarthritis - phenotypes need to be defined and order of Rx may be v Impt. Well, it is really difficult @RheumNow #ACR22 session 12S127 https://t.co/x3bkUP590A